Alfred L. Garfall, MD, discusses long-term follow-up data from the MajesTEC-1 study presented at ASCO 2024. 1. Discuss the data presented at ASCO 2024 on long-term follow-up of patients receiving ...
Community-site step-up dosing required proximity within 60 minutes, an adult caregiver for 48 hours, and twice-daily home temperature/SpO₂ checks with weekday clinic touchpoints. Prophylactic ...
The updated labeling is based on results from a safety management cohort from the ZUMA-1 study. The Food and Drug Administration (FDA) has approved updated labeling for Yescarta ® (axicabtagene ...
During an interview at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Paolo Tarantino, MD, of the Dana ...
Please provide your email address to receive an email when new articles are posted on . Among experienced operators, prophylactic nitroglycerin did not prevent radial artery spasm during transradial ...
Please provide your email address to receive an email when new articles are posted on . The FDA updated the prescribing information for axicabtagene ciloleucel to allow the use of prophylactic ...
PTCY offers improved progression-free and overall survival compared to ATG in MDS patients undergoing allo-HSCT. PTCY is associated with lower rates of grade 2 to 4 acute GVHD but has delayed ...
The patent’s assignee is Continuous Motionflow, Llc. News editors obtained the following quote from the background information supplied by the inventors: “It is estimated that more than a million ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results